Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Minority Interest: 2020-2025

Historic Minority Interest for ImmunityBio (IBRX) over the last 5 years, with Sep 2025 value amounting to $909,000.

  • ImmunityBio's Minority Interest fell 7.81% to $909,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $909,000, marking a year-over-year decrease of 7.81%. This contributed to the annual value of $969,000 for FY2024, which is 7.71% down from last year.
  • As of Q3 2025, ImmunityBio's Minority Interest stood at $909,000, which was down 2.26% from $930,000 recorded in Q2 2025.
  • ImmunityBio's 5-year Minority Interest high stood at $1.1 million for Q3 2023, and its period low was -$3.1 million during Q2 2023.
  • For the 3-year period, ImmunityBio's Minority Interest averaged around $282,091, with its median value being $969,000 (2024).
  • In the last 5 years, ImmunityBio's Minority Interest plummeted by 523.95% in 2022 and then soared by 145.00% in 2023.
  • ImmunityBio's Minority Interest (Quarterly) stood at -$1.7 million in 2021, then plummeted by 43.28% to -$2.5 million in 2022, then spiked by 142.12% to $1.1 million in 2023, then decreased by 7.71% to $969,000 in 2024, then fell by 7.81% to $909,000 in 2025.
  • Its Minority Interest stands at $909,000 for Q3 2025, versus $930,000 for Q2 2025 and $949,000 for Q1 2025.